Long Noncoding RNA LINC00673 Promotes the Proliferation and Metastasis of Epithelial Ovarian Cancer by Associating with Opioid Growth Factor Receptor

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Sep 10

PMID 31496722

Citations 7

Authors

Tingting Zheng

Junjun Qiu

ChunBo Li

Xiaojing Lin

Xiaoyan Tang

Keqin Hua

Affiliations

Soon will be listed here.

Abstract

Purpose: The long noncoding RNA LINC00673 has emerged as an important regulator of cancer development and progression. However, the clinical significance and biological roles of LINC00673 in epithelial ovarian cancer (EOC) remain unclear. In this study, we aimed to explore the oncogenic roles and underlying molecular mechanisms of LINC00673 in EOC.

Patients And Methods: The expression levels of LINC00673 in EOC tissues and cell lines were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Real-time cellular analysis (RTCA), flow cytometry, and transwell assays were conducted to investigate cell proliferation, apoptosis, migration and invasion in vitro. Subcutaneous transplanted tumors were established to explore the oncogenic role of LINC00673 in vivo. Differentially expressed genes were analyzed using transcriptome sequencing. Protein levels were determined by Western blot assays.

Results: LINC00673 was upregulated in EOC tissues and cell lines compared to their corresponding normal controls. High expression of LINC00673 was associated with advanced International Federation of Gynecology and Obstetrics (FIGO) stage, serous histological subtype, lymph node metastasis and poor prognosis in patients with EOC. LINC00673 was also identified as an independent prognostic factor for EOC. In addition, LINC00673 promoted cell migration, invasion and proliferation and inhibited cell apoptosis in vitro and induced tumor growth in vivo. Mechanistically, opioid growth factor receptor () was found to be a potential downstream target gene that mediated the oncogenic effect of LINC00673 in EOC.

Conclusion: LINC00673 contributes to EOC proliferation and metastasis and may be a promising prognostic biomarker for EOC patients.

Citing Articles

LINC00673 binds with leptin to regulate osteogenic function in periodontal ligament stem cells.

Yang Y, Yang P, Zhang Y, Wu Z, Wang X, Zhang J J Orthop Surg Res. 2025; 20(1):165.

PMID: 39953568 PMC: 11827204. DOI: 10.1186/s13018-025-05562-0.

The Opioid Growth Factor in Growth Regulation and Immune Responses in Cancer.

Hankins G, Harris R Adv Neurobiol. 2024; 35:45-85.

PMID: 38874718 DOI: 10.1007/978-3-031-45493-6_4.

Pan-Cancer Analysis and Validation of Opioid-Related Receptors Reveals the Immunotherapeutic Value of Toll-Like Receptor 4.

Wu S, Chen J, Huang E, Zhang Y Int J Gen Med. 2023; 16:5527-5548.

PMID: 38034898 PMC: 10683661. DOI: 10.2147/IJGM.S434076.

The Prognostic Value of LncRNA SLNCR1 in Cancers: A Meta-Analysis.

Cong L, Sun H, Hao M, Sun Q, Zheng Y, Cong X J Oncol. 2021; 2021:3161714.

PMID: 34733328 PMC: 8560271. DOI: 10.1155/2021/3161714.

ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.

Li Y, Fei H, Lin Q, Liang F, You Y, Li M Oncogene. 2021; 40(32):5131-5141.

PMID: 34211089 PMC: 8363099. DOI: 10.1038/s41388-021-01913-3.

References

Hessels D, Klein Gunnewiek J, van Oort I, Karthaus H, van Leenders G, van Balken B . DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003; 44(1):8-15; discussion 15-6. DOI: 10.1016/s0302-2838(03)00201-x. View

Zagon I, Verderame M, McLaughlin P . The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides. 2003; 37(5):290-7. DOI: 10.1016/j.npep.2003.07.001. View

Panzitt K, Tschernatsch M, Guelly C, Moustafa T, Stradner M, Strohmaier H . Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007; 132(1):330-42. DOI: 10.1053/j.gastro.2006.08.026. View

Cheng F, McLaughlin P, Verderame M, Zagon I . The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer. 2008; 7:5. PMC: 2253554. DOI: 10.1186/1476-4598-7-5. View

Cheng F, McLaughlin P, Verderame M, Zagon I . The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell. 2008; 20(1):319-27. PMC: 2613082. DOI: 10.1091/mbc.e08-07-0681. View

Cheng F, McLaughlin P, Verderame M, Zagon I . Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med (Maywood). 2009; 234(5):532-41. DOI: 10.3181/0901-RM-16. View

Zagon I, Donahue R, McLaughlin P . Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol. 2009; 297(4):R1154-61. DOI: 10.1152/ajpregu.00414.2009. View

Gupta R, Shah N, Wang K, Kim J, Horlings H, Wong D . Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464(7291):1071-6. PMC: 3049919. DOI: 10.1038/nature08975. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

10.

Zhou Y, Zhang X, Klibanski A . MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012; 48(3):R45-53. PMC: 3738193. DOI: 10.1530/JME-12-0008. View

11.

Qiu J, Lin Y, Ye L, Ding J, Feng W, Jin H . Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecol Oncol. 2014; 134(1):121-8. DOI: 10.1016/j.ygyno.2014.03.556. View

12.

Kim J, Ahn H, Kim J, Kim J, Lee S, Chae H . Morphine Suppresses Lung Cancer Cell Proliferation Through the Interaction with Opioid Growth Factor Receptor: An In Vitro and Human Lung Tissue Study. Anesth Analg. 2016; 123(6):1429-1436. DOI: 10.1213/ANE.0000000000001293. View

13.

Zheng J, Huang X, Tan W, Yu D, Du Z, Chang J . Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nat Genet. 2016; 48(7):747-57. DOI: 10.1038/ng.3568. View

14.

Yu J, Liu Y, Gong Z, Zhang S, Guo C, Li X . Overexpression long non-coding RNA LINC00673 is associated with poor prognosis and promotes invasion and metastasis in tongue squamous cell carcinoma. Oncotarget. 2017; 8(10):16621-16632. PMC: 5369989. DOI: 10.18632/oncotarget.14200. View

15.

Huang M, Hou J, Wang Y, Xie M, Wei C, Nie F . Long Noncoding RNA LINC00673 Is Activated by SP1 and Exerts Oncogenic Properties by Interacting with LSD1 and EZH2 in Gastric Cancer. Mol Ther. 2017; 25(4):1014-1026. PMC: 5383578. DOI: 10.1016/j.ymthe.2017.01.017. View

16.

Chen S, Liang H, Yang H, Zhou K, Xu L, Liu J . LincRNa-p21: function and mechanism in cancer. Med Oncol. 2017; 34(5):98. DOI: 10.1007/s12032-017-0959-5. View

17.

Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H . Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Mol Cancer. 2017; 16(1):118. PMC: 5504775. DOI: 10.1186/s12943-017-0685-9. View

18.

Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H . Erratum to: Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Mol Cancer. 2017; 16(1):144. PMC: 5574224. DOI: 10.1186/s12943-017-0716-6. View

19.

Ba M, Long H, Cui S, Gong Y, Yan Z, Wu Y . Long noncoding RNA LINC00673 epigenetically suppresses KLF4 by interacting with EZH2 and DNMT1 in gastric cancer. Oncotarget. 2017; 8(56):95542-95553. PMC: 5707041. DOI: 10.18632/oncotarget.20980. View

20.

Zhang L, Zhou X, Zhou R, Lv H, Li W . Long non-coding RNA LINC00673 promotes hepatocellular carcinoma progression and metastasis through negatively regulating miR-205. Am J Cancer Res. 2018; 7(12):2536-2544. PMC: 5752693. View